Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GvHD prophylaxis comparison after unrelated donor stem cell transplantation
ISRCTN50290131Phase 2Active, not recruiting
- Sponsor
- University of Birmingham
- Start
- Feb 2021
- Modality
- Small Molecules, Peptides, Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, open-label trial of antithymocyte globulin, cyclophosphamide, sirolimus, cyclosporine and mycophenolate mofetil in graft-versus-host disease (GVHD) (3 arms), sponsored by University of Birmingham. Primary endpoint: GvHD-free, relapse-free survival. Started Feb 2021; status: active, not recruiting.
02
Drugs
antithymocyte globulincyclophosphamidesirolimuscyclosporinemycophenolate mofetil
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on ISRCTN50290131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN50290131.